A Rollover Study of CC-122

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

February 25, 2026

Study Completion Date

February 25, 2026

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

CC-122

Specified dose on specified days

DRUG

Dexamethasone

Specified dose on specified days

Trial Locations (7)

1105

Local Institution - 400, Amsterdam

10065

Local Institution - 100, New York

13273

Local Institution - 301, Marseille

33076

Local Institution - 300, Bordeaux

37203

Local Institution - 101, Nashville

53792

Local Institution - 102, Madison

1358550

Local Institution - 500, Koto-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05688475 - A Rollover Study of CC-122 | Biotech Hunter | Biotech Hunter